EUVIMEDEUVIMED entdecken
Crossref

Repurposing of FDA-approved drugs against oligomerization domain of dengue virus NS1 protein: a computational approach

Dwaipayan Chaudhuri, Medha Ghosh, Satyabrata Majumder, Kalyan Giri

Molecular Diversity · 2025

DOI: 10.1007/s11030-024-10936-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Diversity, 2025. Verfasst von Dwaipayan Chaudhuri und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Life Sciences, Presidency University, 86/1 College Street, Kolkata, 700073, India. Hauptthemen laut MEDLINE: Viral Nonstructural Proteins, Drug Repositioning, Dengue Virus, Antiviral Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 59 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dengue fever is a serious health hazard on a global scale and its primary causative agent is the dengue virus (DENV). The non-structural protein 1 (NS1) of DENV plays a pivotal role in pathogenesis. It is associated with several autoimmune events, endothelial cell apoptosis, and vascular leakage, which increase mainly during the critical phase of infection. In this study, important residues of the oligomerization domain of NS1 protein were identified by literature searches. Virtual screening has been conducted using the entire dataset of the DrugBank database and the potential small-molecule inhibitors against the NS1 protein have been chosen on the basis of binding energy values. This is succeeded by molecular dynamics (MD) simulations of the shortlisted compounds, ultimately giving rise to five compounds. These five compounds were further subjected to RAMD simulations by applying a random direction force of specific magnitude on the ligand center of mass in order to push the ligand out of the protein-binding pocket, for the quantitative estimation of their binding energy values to determine the interaction strength between protein and ligand which prevents ligand unbinding from its binding site, ultimately leading to the selection of three major compounds, DB00826 (Natamycin), DB11274 (Dihydro-alphaergocryptine), and DB11275 (Epicriptine), with the DB11274 having a role against idiopathic Parkinson's disease, and thus may have possible important roles in the prevention of dengue-associated Parkinsonism. These compounds may act as prospective drugs against dengue, by preventing the oligomerization of the NS1 protein, thereby preventing disease progression and pathogenesis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Viral Nonstructural ProteinsDrug RepositioningDengue VirusAntiviral AgentsMolecular Dynamics SimulationMolecular Docking SimulationBinding SitesProtein BindingHumansLigandsDengueUnited States Food and Drug Administration

Stichwörter der Autor:innen

Dengue virus NS1 oligomerizationMD simulationMM/PBSA binding energyRandom acceleration molecular dynamics simulationVirtual screening

Substanzen

Viral Nonstructural ProteinsAntiviral AgentsLigands

Autor:innen und Institutionen

  • Department of Life Sciences, Presidency University, 86/1 College Street, Kolkata, 700073, India.
  • Department of Life Sciences, Presidency University, 86/1 College Street, Kolkata, 700073, India. kalyan.dbs@presiuniv.ac.in.

Zitieren

APA

Chaudhuri, D., Ghosh, M., Majumder, S., & Giri, K. (2025). Repurposing of FDA-approved drugs against oligomerization domain of dengue virus NS1 protein: a computational approach. Molecular Diversity. https://doi.org/10.1007/s11030-024-10936-3

Vancouver

Chaudhuri D, Ghosh M, Majumder S, Giri K. Repurposing of FDA-approved drugs against oligomerization domain of dengue virus NS1 protein: a computational approach. Molecular Diversity. 2025. doi:10.1007/s11030-024-10936-3

BibTeX
@article{Chaudhuri2025,
  author = {Chaudhuri, Dwaipayan and Ghosh, Medha and Majumder, Satyabrata and Giri, Kalyan},
  title = {Repurposing of FDA-approved drugs against oligomerization domain of dengue virus NS1 protein: a computational approach},
  journal = {Molecular Diversity},
  year = {2025},
  doi = {10.1007/s11030-024-10936-3}
}
Kostenlos starten →